Both Promoter and Institution holdings for Sandu Pharmaceuticals remain unchanged, indicating a lack of confidence from 'smart money'.

Public shareholding has decreased by 1.57% YoY, contrasting with the sector's stability, highlighting potential disinterest among retail investors.

Comparatively, the sector shows no significant movement in shareholding patterns, reinforcing the notion of broad-based selling across the board.